Open access · CC-BY
via OpenAlex
Plasma Microbiome in COVID-19 Subjects: An Indicator of Gut Barrier Defects and Dysbiosis
Ram Prasad, Michael John Patton, Jason L. Floyd, Cristiano Pedrozo Vieira, Seth Fortmann, Mariana DuPont, Angie Harbour, Chen See Jeremy, Justin Wright, Regina Lamendella, Bruce R. Stevens, Maria B. Grant
International Journal of Molecular Sciences · 2022 · ▲ 78 citations
Abstract
The gut is a well-established route of infection and target for viral damage by SARS-CoV-2. This is supported by the clinical observation that about half of COVID-19 patients exhibit gastrointestinal (GI) complications. We aimed to investigate whether the analysis of plasma could provide insight into gut barrier dysfunction in patients with COVID-19 infection. Plasma samples of COVID-19 patients (n = 146) and healthy individuals (n = 47) were collected during hospitalization and routine visits. Plasma microbiome was analyzed using 16S rRNA sequencing and gut permeability markers including fatty acid binding protein 2 (FABP2), peptidoglycan (PGN), and lipopolysaccharide (LPS) in both patient cohorts. Plasma samples of both cohorts contained predominately Proteobacteria, Firmicutes, Bacteroides, and Actinobacteria. COVID-19 subjects exhibit significant dysbiosis (p = 0.001) of the plasma microbiome with increased abundance of Actinobacteria spp. (p = 0.0332), decreased abundance of Bacteroides spp. (p = 0.0003), and an increased Firmicutes:Bacteroidetes ratio (p = 0.0003) compared to healthy subjects. The concentration of the plasma gut permeability marker FABP2 (p = 0.0013) and the gut microbial antigens PGN (p < 0.0001) and LPS (p = 0.0049) were significantly elevated in COVID-19 patients compared to healthy subjects. These findings support the notion that the intestine may represent a source for bacteremia and contribute to worsening COVID-19 outcomes. Therapies targeting the gut and prevention of gut barrier defects may represent a strategy to improve outcomes in COVID-19 patients.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.3390/ijms23169141
- Canonical
- link ↗
- Fetched
- 2026-11-06 MST
Cite this
APA
Prasad, R., Patton, M.J., Floyd, J.L., Vieira, C.P., Fortmann, S., DuPont, M., Harbour, A., Jeremy, C.S., Wright, J., Lamendella, R., Stevens, B.R., & Grant, M.B. (2022). Plasma Microbiome in COVID-19 Subjects: An Indicator of Gut Barrier Defects and Dysbiosis. <em>International Journal of Molecular Sciences</em>. https://doi.org/10.3390/ijms23169141
Vancouver
Prasad R, Patton MJ, Floyd JL, Vieira CP, Fortmann S, DuPont M, et al. Plasma Microbiome in COVID-19 Subjects: An Indicator of Gut Barrier Defects and Dysbiosis. International Journal of Molecular Sciences. 2022. doi:10.3390/ijms23169141.
BibTeX
@article{ram2022Plasma,
title = {Plasma Microbiome in COVID-19 Subjects: An Indicator of Gut Barrier Defects and Dysbiosis},
author = {Ram Prasad and Michael John Patton and Jason L. Floyd and Cristiano Pedrozo Vieira and Seth Fortmann and Mariana DuPont and Angie Harbour and Chen See Jeremy and Justin Wright and Regina Lamendella and Bruce R. Stevens and Maria B. Grant},
journal = {International Journal of Molecular Sciences},
year = {2022},
doi = {10.3390/ijms23169141},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Springer eBooks 2022
Citation only
Use of Prebiotics for Addressing Gut Dysbiosis and Achieving Healthy Gut–Brain Axis
Annals of the Rheumatic Diseases 2024
Citation only
AB0346 GUT MICROBIOME DYSBIOSIS IN ASIAN PATIENTS WITH KNEE OSTEOARTHRITIS
Frontiers in Cellular and Infection Microbiology 2019
Open access · CC-BY
Gut Microbiota Dysbiosis and Increased Plasma LPS and TMAO Levels in Patients With Preeclampsia
Nature Reviews Gastroenterology & Hepatology 2022
Open access · OA
The gut microbiome as a modulator of healthy ageing
Gut 2022
Preprint · OA
Gut microbiota regulate Alzheimer’s disease pathologies and cognitive disorders via PUFA-associated neuroinflammation
Translational research 2025
Open access · CC-BY